BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.33
-0.10 (-1.19%)
At close: Jun 9, 2026, 4:00 PM EDT
8.48
+0.15 (1.80%)
After-hours: Jun 9, 2026, 7:29 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 435 employees as of December 31, 2025. The number of employees decreased by 145 or -25.00% compared to the previous year.
Employees
435
Change (1Y)
-145
Growth (1Y)
-25.00%
Revenue / Employee
$2,036,129
Profits / Employee
-$1,052,834
Market Cap
2.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | -145 | -25.00% |
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,796 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
BCRX News
- 6 hours ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 13 days ago - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 27 days ago - BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - GlobeNewsWire
- 4 weeks ago - BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - BioCryst price target raised to $28 from $25 at Citizens - TheFly
- 4 weeks ago - BioCryst reports Q1 EPS ($2.98), consensus 11c - TheFly
- 4 weeks ago - BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts